Abstract：
:Percutaneous coronary intervention (PCI) has significantly improved clinical outcomes in coronary artery disease patients. Since PCI is associated with platelet activation, antiplatelet therapy with aspirin, clopidogrel and GPIIb/IIIa inhibitors comprise the cornerstone strategy during and following PCI. The latter agents are arguably the most important drugs we administer to the patient with established coronary artery disease since they are specifically given to prevent the most catastrophic event, the formation of an occlusive arterial thrombus. Numerous clinical trials have confirmed the efficacy of antiplatelet therapy in attenuating recurrent ischaemic event occurrence. Despite the extensive use of antiplatelet therapies, ischaemic event occurrence such as post-procedural myocardial infarction and stent thrombosis still remains an important concern and highlights the need for improved treatment strategies. A major limitation of current treatment is the application of a "one size fits all" strategy advocated by the guidelines that completely ignores the evaluation of the individual antiplatelet response. Pharmacodynamic studies have revealed the limitations of aspirin and clopidogrel treatment that include response variability, and a high prevalence of antiplatelet non-responsiveness associated with significant risk for recurrent ischemic event occurrence. Thus, two major paradoxes in cardiovascular medicine today are: 1) despite the overwhelming evidence that platelet reactivity strongly influences the development of potentially catastrophic events including myocardial infarction and stent thrombosis in the PCI patient, no measurement is made in clinical practice to assess the presence of blood vulnerability (platelet reactivity) and 2) despite the overwhelming evidence that the effect of dual antiplatelet therapy with aspirin and P2Y12 receptor blockers is variable, the guidelines largely recommend a uniform, "one size fits all" dosing of these agents in the PCI patient without any confirmation of an adequate antiplatelet effect.
journal_name
Hamostaseologiejournal_title
Hamostaseologieauthors
Tantry US,Gurbel PAsubject
Has Abstractpub_date
2009-11-01 00:00:00pages
368-75issue
4eissn
0720-9355issn
2567-5761pii
09040368journal_volume
29pub_type
杂志文章,评审相关文献
Hamostaseologie文献大全abstract：UNLABELLED:A protein Z deficiency is presumably related with a threefold risk of venous and arterial thrombosis. Mucosal bleedings and post-operative haematomas can occur more frequently. This is seen in an increased in vivo bleeding time without other plasmatic coagulation disorders or thrombopathies. Pregnancy compli...
journal_title：Hamostaseologie
pub_type： 杂志文章
doi：
更新日期：2012-01-01 00:00:00
abstract：:When assessing the quality of clinical trials in intermittent claudication, on principle the same strict biometric and medical standards need to be applied for studies on the effect of walking exercise as for conservative drug treatment studies. However, as demonstrated by a recent review of the Cochrane Collaboration...
journal_title：Hamostaseologie
pub_type： 杂志文章,评审
doi：
更新日期：2006-08-01 00:00:00
abstract：:The impact of inherited bleeding disorders on the socioeconomic status (SES) of affected individuals is not clear. The SES of adult patients with congenital bleeding disorders (PWBD) from a centre in Germany (age 42.3 ± 15.0 years) was compared to that of a gender- and age-matched control group of patients with thromb...
journal_title：Hamostaseologie
pub_type： 杂志文章
doi：10.5482/HAMO-16-12-0047
更新日期：2018-08-01 00:00:00
abstract：OBJECTIVE: This article aims to analyze the phenotype and genotype of an inherited dysfibrinogenemia pedigree associated with a heterozygous mutation in the FGA gene, and to investigate the pathogenesis of this disease. CLINICAL PRESENTATION: The proband of interest is a 29-year-old woman. She was in her 37 weeks of g...
journal_title：Hamostaseologie
pub_type： 杂志文章
doi：10.1055/a-1261-3884
更新日期：2020-12-01 00:00:00
abstract：:Thrombocytosis (defined as platelets >450 x 109/l) has several aetiologies. After having excluded spurious thrombocytosis (e. g., due to microspherocytes, schistocytes, cryoglobulins, or bacteria), the differential diagnosis of true thrombocytosis encompasses secondary causes (as diverse as inflammation, infection, ma...
journal_title：Hamostaseologie
pub_type： 杂志文章,评审
doi：10.5482/HAMO-14-11-0074
更新日期：2016-11-07 00:00:00
abstract：:Replacement therapy of coagulation factor preparations (AT, FFP, PPSB, FXIII, rFVIIa) are frequently used on the Intensive Care Units. Indications, dosage, specific effects and side effects have to be considered. ...
journal_title：Hamostaseologie
pub_type： 杂志文章,评审
doi：10.1267/hämo05020209
更新日期：2005-05-01 00:00:00
abstract：:Patients with diabetes are at increased risk of cardiovascular morbidity and mortality. While arteriosclerotic lesions have long been recognized as the underlying cause more recent studies suggest that alterations of the blood are also critically involved. Following plaque rupture, adherence of platelets is followed b...
journal_title：Hamostaseologie
pub_type： 杂志文章
doi：10.5482/HAMO-14-09-0039
更新日期：2015-01-01 00:00:00
abstract：:Upon vascular injury or tissue damage, the exposed intracellular material such as nucleic acids, histones and other macromolecules may come into contact with vessel wall cells and circulating blood cells and may thus, have an enduring influence on wound healing and body defence processes. This short review summarizes ...
journal_title：Hamostaseologie
pub_type： 杂志文章,评审
doi：10.5482/HAMO-13-01-0001
更新日期：2013-01-01 00:00:00
abstract：:Von Willebrand factor (VWF) structure-function relationship has been studied only through in vitro approaches. The VWF-deficient mouse model has been extremely useful to examine the in vivo function of VWF but does not allow a more subtle analysis of the relative importance of its different domains. However, consideri...
journal_title：Hamostaseologie
pub_type： 杂志文章
doi：
更新日期：2009-01-01 00:00:00
abstract：:Characteristic features of disseminated intravascular coagulation (DIC) are the opposing risks of bleeding (due to consumptive coagulopathy and hyperfibrinolysis) and organ failure (due to widespread microvascular thromboses). The purpose of anticoagulation in DIC is to attenuate excessive thrombin generation and fibr...
journal_title：Hamostaseologie
pub_type： 杂志文章
doi：10.1055/s-0038-1675386
更新日期：2019-08-01 00:00:00
abstract：:Epidemiological studies revealed that most antineoplastic agents and regimes enhance the risk of venous and arterial thromboembolic events in cancer patients. The purpose of this article is to review clinical and pathophysiological data related to chemotherapy-associated thromboembolism under special consideration of ...
journal_title：Hamostaseologie
pub_type： 杂志文章,评审
doi：
更新日期：2009-01-01 00:00:00
abstract：:Recurrent venous thromboembolism is associated with increased mortality in 5-9% of the patients. On the other hand prolonged anticoagulation can increase the bleeding risk which can also be responsible for an increased mortality. Therefore, it is necessary to validate the recurrence risk of venous thromboembolism on a...
journal_title：Hamostaseologie
pub_type： 杂志文章,评审
doi：10.5482/ha-1144
更新日期：2011-02-01 00:00:00
abstract：:Current antithrombotic therapy in patients with acute coronary syndrome (ACS) comprises antiplatelet and anticoagulant therapy. Dual antiplatelet therapy composed of aspirin plus a third generation P2Y12 inhibitor (prasugrel or ticagrelor) represents the gold standard, while aspirin plus second generation P2Y12 inhibi...
journal_title：Hamostaseologie
pub_type： 杂志文章,评审
doi：10.5482/HAMO-13-09-0048
更新日期：2014-01-01 00:00:00
abstract：UNLABELLED:Secondary arthrosis of the upper ankle joint (talocalcanean joint) is one of the most frequent forms of haemophilic arthropathy. It is a secondary form of arthrosis not only because of chronic synovitis and cartilage injury resulting from chronic recurrent intraarticular bleeds, but also due to the misalignm...
journal_title：Hamostaseologie
pub_type： 杂志文章
doi：
更新日期：2009-10-01 00:00:00
abstract：:Acquired haemophilia A (AHA) is a rare autoimmune disease caused by antibodies directed against clotting factor VIII. About half of cases are idiopathic, but AHA may also be secondary to autoimmune, dermatologic, or oncologic diseases. In approximately 10% of non-idiopathic cases, the disease occurs after or with the ...
journal_title：Hamostaseologie
pub_type： 杂志文章
doi：10.1055/s-0038-1668570
更新日期：2019-02-01 00:00:00
abstract：UNLABELLED:With the development of clotting-factors in the seventies the haemophilia patients were released from being handicapped and began to live a quite normal life. Thus, psychosocial counselling did not seem to be necessary. But the impact of HIV-infection to the world of haemophilia was so intense that professio...
journal_title：Hamostaseologie
pub_type： 杂志文章
doi：
更新日期：2010-11-01 00:00:00
abstract：:The DHR (Deutsches Hämophilieregister, German Haemophilia Register) records patient data on haemophilia A, haemophilia B, von Willebrand disease, and other coagulation factor deficiency disorders. The DHR has been online since 2009. The participation in the DHR leads to additional administrative workload for the hospi...
journal_title：Hamostaseologie
pub_type： 杂志文章
doi：
更新日期：2010-11-01 00:00:00
abstract：UNLABELLED:In recent years thrombophilia has gained much attention as a risk factor for pregnancy complications. Whereas there is an established correlation between antiphospholipid-antibodies and pregnancy loss, data for other risk factors of thrombosis are less well established. Data suggest associations with antithr...
journal_title：Hamostaseologie
pub_type： 杂志文章
doi：
更新日期：2008-01-01 00:00:00
abstract：:Several challenges arise from the wide application of molecular genetic analyses, among them the need to introduce rules to evaluate molecular genetic test systems as well as test laboratories. This article specifically addresses laboratories performing molecular genetic tests for diagnosis, prevention and therapy of ...
journal_title：Hamostaseologie
pub_type： 杂志文章
doi：
更新日期：2010-05-01 00:00:00
abstract：:For the last decades, anticoagulation for stroke prevention in atrial fibrillation (AF) as well as for the prophylaxis and long-term treatment of venous thromboembolism has been entirely based on vitamin K antagonists (VKA). Although very effective under optimal conditions, long-term treatment with these drugs is flaw...
journal_title：Hamostaseologie
pub_type： 杂志文章,评审
doi：10.5482/ha-12050008
更新日期：2012-01-01 00:00:00
abstract：:By the use of conventional anticoagulants, significant improvements were achieved in all fields of medicine. Although efficacious and widely used, their use is limited in several respects. In particular, the use of vitamin K antagonists is restricted in the clinical routine setting. The main reasons are the delayed on...
journal_title：Hamostaseologie
pub_type： 杂志文章,评审
doi：
更新日期：2002-08-01 00:00:00
abstract：:Patients with myeloproliferative neoplasms (MPNs), such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are at increased risk for arterial and venous thrombosis/thromboembolism. In particular, the risk of splanchnic venous thrombosis, such as portal vein thrombosis or Budd-Chiari syndrome, ...
journal_title：Hamostaseologie
pub_type： 杂志文章,评审
doi：10.1055/s-0040-1701474
更新日期：2020-02-01 00:00:00
abstract：:The antiphospholipid syndrome is defined as the occurrence of one or more episodes of vascular thrombosis and/or miscarriage together with antiphospholipid antibodies. Some of these antibodies can be detected via coagulation assays by prolonging phospholipids-dependent assays. These unspecific inhibitors are termed lu...
journal_title：Hamostaseologie
pub_type： 杂志文章,评审
doi：10.1267/hämo05010050
更新日期：2005-02-01 00:00:00
abstract：:Recent advances in the diagnosis and the treatment of acute coronary syndromes (ACS) have led to a substantial reduction of major coronary events, to an improvement in patient outcome and the definition of new guidelines. Current strategies for the treatment of patients with non-ST-elevation ACS recommend a combined a...
journal_title：Hamostaseologie
pub_type： 杂志文章
doi：
更新日期：2007-12-01 00:00:00
abstract：:Von Willebrand disease (VWD) is known for its marked heterogeneity which was already recognized by von Willebrand in 1926. The basis of phenotypic differentiation are quantitative and qualitative or functional differences between the different types and subtypes of VWD. One of the most important tools in the classific...
journal_title：Hamostaseologie
pub_type： 杂志文章,评审
doi：10.1267/hamo04010027
更新日期：2004-02-01 00:00:00
abstract：:This is a very short review on quantitative coagulation factor assays for the beginner. For systematic training several excellent textbooks in German language are available. Quantitative functional assays of coagulation factors and of physiological inhibitor proteins are based on the principle of parallel-line or slop...
journal_title：Hamostaseologie
pub_type： 杂志文章,评审
doi：
更新日期：2006-01-01 00:00:00
abstract：:This article reviews the current understanding of the pathophysiology of acute coronary syndrome and how these concepts have altered our clinical approach to the acute phase of coronary heart disease. Thrombosis due to erosion or, in most cases, rupture of a vulnerable atherosclerotic plaque underlies most acute coron...
journal_title：Hamostaseologie
pub_type： 杂志文章,评审
doi：
更新日期：2006-05-01 00:00:00
abstract：AIM:In children, screening for haemorrhagic disorders is further complicated by the fact that infants and young children with mild disease in many cases most likely will not have a significant history of easy bruising or bleeding making the efficacy of a questionnaire even more questionable. PATIENTS, METHODS:We compa...
journal_title：Hamostaseologie
pub_type： 杂志文章
doi：
更新日期：2009-10-01 00:00:00
abstract：UNLABELLED:Antibodies against annexin-V, a potent anticoagulant abundant in placental tissues, were recently controversially reported to be associated with recurrent miscarriages or failures of in-vitro-fertilization (IVF) attempts. PATIENTS, MATERIAL, METHODS:We screened 56 women (34.7 +/- 4.3 years of age: mean +/- ...
journal_title：Hamostaseologie
pub_type： 杂志文章
doi：
更新日期：2005-11-01 00:00:00
abstract：:Recombinant activated factor VII (rFVIIa) is a pro-haemostatic agent that can be used for patients with haemophilia and inhibiting antibodies towards a coagulation factor. Recombinant factor VIIa is, however, increasingly used for several other indications, including patients who experience serious and life-threatenin...
journal_title：Hamostaseologie
pub_type： 杂志文章
doi：
更新日期：2009-01-01 00:00:00
